{"title":"Estimating the time required to reach HPV vaccination targets across Europe.","authors":"Ilias Gountas,Mohammed Aman,Deepak Alexander,Robert Hughes,Georgie Weston,Ugne Sabale","doi":"10.1080/14760584.2024.2402535","DOIUrl":"https://doi.org/10.1080/14760584.2024.2402535","url":null,"abstract":"BACKGROUNDCervical cancer (CC) is one of the most common causes of cancer-related deaths in women. The World Health Organization (WHO) has called for the CC elimination as a public health priority and has urged countries to achieve a 90% vaccine coverage rate of human papilloma virus (HPV) vaccination among 15-year-old girls by 2030.RESEARCH DESIGN AND METHODSRegression models were fitted to the WHO HPV vaccine coverage rate data to estimate when the 90% vaccine coverage rate target would be achieved in 22 European countries.RESULTSThe mean vaccine coverage rate of included countries was 62.2% (SD: 18.3). Nine countries (Iceland, Norway, Portugal, Ireland, Hungary, Spain, Sweden, Denmark, and Switzerland) are expected to achieve a 90% vaccine coverage rate by 2030. Six countries (Estonia, Cyprus, Netherlands, France, Germany, and Italy) are expected to reach a 90% vaccine coverage rate between 2030 and 2040 whereas seven countries (Belgium, Bulgaria, Finland, Latvia, Luxembourg, Malta, and Slovenia) are not expected to achieve the 90% vaccine coverage rate target by 2040.CONCLUSIONThe majority of European countries are not on track to achieve 90% vaccine coverage rate by 2030. To achieve this, a significant increase in the annual vaccine coverage rate growth rate is required.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"21 1","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mary Bausch-Jurken,Rachel S Dawson,Francesca Ceddia,Veronica Urdaneta,Morgan A Marks,Yohei Doi
{"title":"A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines.","authors":"Mary Bausch-Jurken,Rachel S Dawson,Francesca Ceddia,Veronica Urdaneta,Morgan A Marks,Yohei Doi","doi":"10.1080/14760584.2024.2402955","DOIUrl":"https://doi.org/10.1080/14760584.2024.2402955","url":null,"abstract":"INTRODUCTIONSince the original COVID-19 vaccines were developed, abundant clinical trial and real-world evidence evaluating the efficacy, effectiveness, and safety of COVID-19 vaccines has been collected. Knowledge of the relative benefits and risks of COVID-19 vaccines is essential for building trust within target populations, ensuring they remain effectively and safely protected against an enduring infectious threat.AREAS COVEREDThis descriptive review discusses the benefits and risks associated with marketed Moderna, Inc. mRNA-based COVID-19 vaccines, focusing on their real-world effectiveness and safety profiles in various age groups. Adverse events of interest and potential benefits of vaccination are reviewed, including reduced risk for severe COVID-19 and long-term health outcomes, reduced economic and societal costs, and reduced risk for SARS-CoV-2 transmission.EXPERT OPINIONPost-marketing safety and real-world data for Moderna, Inc. COVID-19 mRNA vaccines strongly support a positive benefit - risk profile favoring vaccination across all age groups. Although COVID-19 is no longer considered a global health pandemic, health risks associated with SARS-CoV-2 infection remain high. Concerted efforts are required to engage communities and maintain protection through vaccination. Continued surveillance of emerging variants and monitoring of vaccine safety and effectiveness are crucial for ensuring sustained protection against SARS-CoV-2.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"81 5 1","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mario Rivera-Izquierdo,Arturo Morales-Portillo,Inmaculada Guerrero-Fernández de Alba,Nicolás Francisco Fernández-Martínez,Joan Antoni Schoenenberger-Arnaiz,José Luis Barranco-Quintana,Carmen Valero-Ubierna
{"title":"Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024.","authors":"Mario Rivera-Izquierdo,Arturo Morales-Portillo,Inmaculada Guerrero-Fernández de Alba,Nicolás Francisco Fernández-Martínez,Joan Antoni Schoenenberger-Arnaiz,José Luis Barranco-Quintana,Carmen Valero-Ubierna","doi":"10.1080/14760584.2024.2401839","DOIUrl":"https://doi.org/10.1080/14760584.2024.2401839","url":null,"abstract":"INTRODUCTIONMonoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules.AREAS COVEREDVaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies.EXPERT OPINIONCurrent recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, that are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"45 1","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142195989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Anti-neuraminidase immunity in the combat against influenza","authors":"Xiaojian Zhang, Ted M. Ross","doi":"10.1080/14760584.2024.2343689","DOIUrl":"https://doi.org/10.1080/14760584.2024.2343689","url":null,"abstract":"Anti-neuraminidase (NA) immunity correlates with the protection against influenza virus infection in both human and animal models. The aim of this review is to better understand the mechanism of an...","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"34 1","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140613032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shanti Pather, Alexander Muik, Ruben Rizzi, Federico Mensa
{"title":"Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary","authors":"Shanti Pather, Alexander Muik, Ruben Rizzi, Federico Mensa","doi":"10.1080/14760584.2024.2320858","DOIUrl":"https://doi.org/10.1080/14760584.2024.2320858","url":null,"abstract":"What are variant-adapted COVID-19 vaccines?The COVID-19 vaccine developed by BioNTech and Pfizer is known as BNT162b2 (Comirnaty). BNT162b2 contains messenger RNA, or mRNA, from SARS-CoV-2. SARS-Co...","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"118 1","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140565870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Expert Review of VaccinesPub Date : 2024-01-01Epub Date: 2024-01-04DOI: 10.1080/14760584.2023.2299401
Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson
{"title":"Modeling undetected poliovirus circulation following the 2022 outbreak in the United States.","authors":"Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson","doi":"10.1080/14760584.2023.2299401","DOIUrl":"10.1080/14760584.2023.2299401","url":null,"abstract":"<p><strong>Background: </strong>New York State (NYS) reported a polio case (June 2022) and outbreak of imported type 2 circulating vaccine-derived poliovirus (cVDPV2) (last positive wastewater detection in February 2023), for which uncertainty remains about potential ongoing undetected transmission.</p><p><strong>Research design and methods: </strong>Extending a prior deterministic model, we apply an established stochastic modeling approach to characterize the confidence about no circulation (CNC) of cVDPV2 as a function of time since the last detected signal of transmission (i.e. poliovirus positive acute flaccid myelitis case or wastewater sample).</p><p><strong>Results: </strong>With the surveillance coverage for the NYS population majority and its focus on outbreak counties, modeling suggests a high CNC (95%) within 3-10 months of the last positive surveillance signal, depending on surveillance sensitivity and population mixing patterns. Uncertainty about surveillance sensitivity implies longer durations required to achieve higher CNC.</p><p><strong>Conclusions: </strong>In populations that maintain high overall immunization coverage with inactivated poliovirus vaccine (IPV), rare polio cases may occur in un(der)-vaccinated individuals. Modeling demonstrates the unlikeliness of type 2 outbreaks reestablishing endemic transmission or resulting in large absolute numbers of paralytic cases. Achieving and maintaining high immunization coverage with IPV remains the most effective measure to prevent outbreaks and shorten the duration of imported poliovirus transmission.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"186-195"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Expert Review of VaccinesPub Date : 2024-01-01Epub Date: 2024-01-08DOI: 10.1080/14760584.2023.2299384
Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer
{"title":"Multiple antigen presenting system (MAPS): state of the art and potential applications.","authors":"Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer","doi":"10.1080/14760584.2023.2299384","DOIUrl":"10.1080/14760584.2023.2299384","url":null,"abstract":"<p><strong>Introduction: </strong>Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality. Here we present an original vaccine platform, the Multiple Antigen Presenting System (MAPS), that relies on high-affinity interactions between a biotinylated polysaccharide (PS) and rhizavidin-fused pathogen-specific proteins. MAPS allows for flexible combinations of various PS and protein components.</p><p><strong>Areas covered: </strong>This narrative review summarizes the underlying principles of MAPS and describes its applications for vaccine design against bacterial and viral pathogens in non-clinical and clinical settings.</p><p><strong>Expert opinion: </strong>The utilization of high-affinity non-covalent biotin-rhizavidin interactions in MAPS allows for combining multiple PS and disease-specific protein antigens in a single vaccine. The modular design enables a simplified exchange of vaccine components. Published studies indicate that MAPS technology may support enhanced immunogenic breadth (covering more serotypes, inducing B- and T-cell responses) beyond that which may be elicited via PS- or protein-based conjugate vaccines. Importantly, a more detailed characterization of MAPS-based candidate vaccines is warranted, especially in clinical studies. It is anticipated that MAPS-based vaccines could be adapted and leveraged across numerous diseases of global public health importance.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"196-204"},"PeriodicalIF":6.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Expert Review of VaccinesPub Date : 2024-01-01Epub Date: 2024-09-24DOI: 10.1080/14760584.2024.2404633
Huanhuan Wang, Juan Wang, Shijie Yan, Gengfan Zhao, Shanzhen Wang, Hong Tao, Ye Xu, Jinfeng Wu
{"title":"Immunogenicity and safety of Vero cell culture-derived Japanese encephalitis vaccine: a phase 3 study in Chinese infants.","authors":"Huanhuan Wang, Juan Wang, Shijie Yan, Gengfan Zhao, Shanzhen Wang, Hong Tao, Ye Xu, Jinfeng Wu","doi":"10.1080/14760584.2024.2404633","DOIUrl":"10.1080/14760584.2024.2404633","url":null,"abstract":"<p><strong>Background: </strong>Japanese encephalitis (JE) is a severe infectious disease of the central nervous system. Vaccination with Vero cell culture-derived vaccines may effectively reduce JE incidence.</p><p><strong>Research design and methods: </strong>In this single-center, randomized, blinded, positive-controlled clinical trial in China involving 600 healthy infants aged 6-11 months, participants were divided into experimental and control groups administered JEV-PI and JEV-LI, respectively. Antibody titers were determined after 0- and 7-day immunization schedules. A booster dose followed 12 months later.</p><p><strong>Results: </strong>After primary vaccination and before booster vaccination, the positive conversion rate, geometric mean titer (GMT), and geometric mean increase (GMI) of JEV-PI-neutralizing antibodies exceeded those of JEV-LI. After booster immunization, the GMT and GMI of JEV-PI were higher than those of JEV-LI. After primary immunization, the local, systemic, and overall adverse reactions were of grades 1 and 2, with a low incidence of grade 3. After booster immunization, these differences were mainly grades 1 and 2, with no differences between JEV-PI and JEV-LI.</p><p><strong>Conclusion: </strong>JEV-PI is a promising vaccine as infants acquired long-lasting and highly neutralizing immune antibodies after inoculation with JEV-PI.</p><p><strong>Trial registration: </strong>The trial was registered in the Chinese Clinical Trial Registry (https://www.chictr.org.cn/showproj.html?proj = 203130; registration number: ChiCTR2300074692; registration date: 14/08/2023).</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"958-965"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Expert Review of VaccinesPub Date : 2024-01-01Epub Date: 2024-10-24DOI: 10.1080/14760584.2024.2417854
Gaetan Gavazzi, Marc Paccalin, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet, Joaquin Mould-Quevedo
{"title":"Cost-effectiveness of cell-based influenza vaccine in France.","authors":"Gaetan Gavazzi, Marc Paccalin, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet, Joaquin Mould-Quevedo","doi":"10.1080/14760584.2024.2417854","DOIUrl":"10.1080/14760584.2024.2417854","url":null,"abstract":"<p><strong>Objectives: </strong>Annually in France, influenza results in over one million GP consultations, around 20,000 hospitalizations, and approximately 9,000 deaths. This study assesses the cost-effectiveness of cell-based quadrivalent influenza vaccine (QIVc) for those under 65, which enhances effectiveness avoiding egg-adaptation, compared to egg-based quadrivalent influenza vaccine (QIVe).</p><p><strong>Methods: </strong>An age-structured susceptible-exposed-infected-recovered (SEIR) transmission model, calibrated to represent an average influenza season based on French data from 2011 to 2019, integrates a contact matrix estimating intergroup contact rates. Evaluating epidemiological, economic and utility outcomes, the model includes vaccine effectiveness and medical costs from the existing literature and French national data. Adjustments to quality of life due to infection and hospitalization are also included. Uncertainty is explored through scenario and sensitivity analyses.</p><p><strong>Results: </strong>Compared to QIVe, QIVc significantly reduces healthcare utilization and mortality, preventing 49,946 GP consultations, 1,087 hospitalizations, and 231 deaths in France. Despite an initial investment of 7.6 million euros, QIVc achieves a net saving of 12 million euros in healthcare expenditures, making it a dominant cost-saving strategy. Probabilistic sensitivity analyses indicate dominance in 78% of 10,000 simulations.</p><p><strong>Conclusions: </strong>Introducing cell-based influenza vaccines in the French immunization program prevents influenza cases, hospitalizations, death, while reducing costs versus egg-based influenza vaccines.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"1020-1028"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Expert Review of VaccinesPub Date : 2024-01-01Epub Date: 2024-06-25DOI: 10.1080/14760584.2024.2369583
Geetha P Bansal, Nirbhay Kumar
{"title":"Immune mechanisms targeting malaria transmission: opportunities for vaccine development.","authors":"Geetha P Bansal, Nirbhay Kumar","doi":"10.1080/14760584.2024.2369583","DOIUrl":"10.1080/14760584.2024.2369583","url":null,"abstract":"<p><strong>Introduction: </strong>Malaria continues to remain a major global health problem with nearly a quarter of a billion clinical cases and more than 600,000 deaths in 2022. There has been significant progress toward vaccine development, however, poor efficacy of approved vaccines requiring multiple immunizing doses emphasizes the need for continued efforts toward improved vaccines. Progress to date, nonetheless, has provided impetus for malaria elimination.</p><p><strong>Areas covered: </strong>In this review we will focus on diverse immune mechanisms targeting gametocytes in the human host and gametocyte-mediated malaria transmission via the mosquito vector.</p><p><strong>Expert opinion: </strong>To march toward the goal of malaria elimination it will be critical to target the process of malaria transmission by mosquitoes, mediated exclusively by the sexual stages, i.e. male, and female gametocytes, ingested from infected vertebrate host. Studies over several decades have established antigens in the parasite sexual stages developing in the mosquito midgut as attractive targets for the development of transmission blocking vaccines (TBVs). Immune clearance of gametocytes in the vertebrate host can synergize with TBVs and directly aid in maintaining effective transmission reducing immune potential.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"645-654"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}